CareDx agreed to acquire Naveris for up to $260 million, seeking expanded access to liquid biopsy monitoring in HPV-driven cancers. The deal provides $160 million upfront, with as much as $100 million tied to revenue milestones, and is designed to add NavDx, Naveris’ tumor-naïve minimal residual disease test measuring circulating viral DNA fragments. CareDx highlighted that the NavDx approach has Medicare coverage for specific HPV-related indications and that Naveris operates high-complexity labs in Massachusetts and North Carolina. Naveris reported about $12 million in unaudited revenue in Q1 2026 and has performed more than 130,000 commercial tests to date. Strategically, the acquisition is positioned as a targeted add-on in a reimbursed niche for longitudinal molecular surveillance, rather than a broad pivot into all MRD testing.